Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Soleno Therapeutics Inc (SLNO) – Soleno Therapeutics Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

SLNO trades at $52.95, up 0.02% on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS expected at $0.73. Revenue grew to $190.41M in 2025, with a net income margin of 33.7% and robust profitability metrics. Analyst consensus is a Buy with a $58.40 price target, though multiple law firms have announced securities class action deadlines for May 5, 2026, related to allegations from March-November 2025.
Outlook is mixed: strong fundamentals and analyst support suggest upside, but legal risks and overbought technicals pose near-term headwinds. Investors should weigh earnings growth potential against litigation uncertainties and current valuation levels.
Read full analysis

Key Stats

  • Market Cap
    $2.76B
  • Sector
    Health
  • 3M Drawdown
    -26.73%
  • Enterprise Value
    $2.56B
  • Dividend Yield
    -
  • Typical Hold Time
    8 days
$52.95
52W Low: $30.05
27 Mar 2026
52W High: $88.49
09 Jul 2025

Soleno Therapeutics Inc (SLNO) is currently valued at a market capitalization of $2.76B, with an enterprise value of $2.56B. Over the past 52 weeks, Soleno Therapeutics Inc has traded between a low of $30.05 and a high of $88.49, highlighting its annual price range. Over the past three months, Soleno Therapeutics Inc has recorded a drawdown of -26.73%, reflecting recent price volatility. On average, investors hold Soleno Therapeutics Inc for approximately 8 days, indicating typical investor behavior on the platform.

About Soleno Therapeutics Inc

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases. The company's lead product candidate, DCCR (Diazoxide Choline Extended-Release), is currently in late-stage clinical trials for the treatment of Prader-Willi Syndrome (PWS), a complex genetic disorder that causes a constant feeling of hunger (hyperphagia). Soleno is committed to addressing the significant unmet medical need in the PWS community.


Technical Indicators
|
|
|
Overall Summary
Bearish (9)Neutral (9)Bullish (9)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $2.76B
  • Sector
    Health
  • 3M Drawdown
    -26.73%
  • Enterprise Value
    $2.56B
  • Dividend Yield
    -
  • Typical Hold Time
    8 days
$52.95
52W Low: $30.05
27 Mar 2026
52W High: $88.49
09 Jul 2025

Soleno Therapeutics Inc (SLNO) is currently valued at a market capitalization of $2.76B, with an enterprise value of $2.56B. Over the past 52 weeks, Soleno Therapeutics Inc has traded between a low of $30.05 and a high of $88.49, highlighting its annual price range. Over the past three months, Soleno Therapeutics Inc has recorded a drawdown of -26.73%, reflecting recent price volatility. On average, investors hold Soleno Therapeutics Inc for approximately 8 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!